<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02900443</url>
  </required_header>
  <id_info>
    <org_study_id>NL57115.058.16</org_study_id>
    <nct_id>NCT02900443</nct_id>
  </id_info>
  <brief_title>Mycophenolate Mofetil Versus Azathioprine in Treatment Naive Autoimmune Hepatitis</brief_title>
  <acronym>CAMARO</acronym>
  <official_title>A Randomised, Open-label Clinical Trial Assessing the Efficacy and Safety of Mycophenolate Mofetil Versus Azathioprine for Induction of Remission in Treatment Naive Autoimmune Hepatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale: Current standard therapy of autoimmune hepatitis consists of a combination of
      prednisolone and azathioprine. However, a significant proportion of patients does not respond
      to, or is intolerant for, azathioprine. Mycophenolate mofetil (MMF) has surpassed
      azathioprine as therapy to prevent organ transplant rejection and is sometimes used as an
      alternative option for autoimmune hepatitis. Several case series and one prospective study
      have documented the efficacy and safety of mycophenolate mofetil as induction therapy for
      autoimmune hepatitis. Robust evidence from a formal randomized clinical trial is lacking.

      Objective: To assess the efficacy and safety of mycophenolate mofetil as induction therapy in
      patients with treatment naive autoimmune hepatitis.

      Study design: Multicenter, randomised, open-label intervention study Study population:
      Patients with newly diagnosed autoimmune hepatitis who are in need of induction therapy
      according to current guidelines.

      Intervention: The intervention group will receive oral mycophenolate mofetil for 24 weeks.
      The control group will be treated with azathioprine for 24 weeks. Both groups will be treated
      with steroid induction which will closely follow the schedule from the recent Clinical
      Practice Guidelines by the European Association for Study of the Liver (EASL).

      Main study parameters/endpoints: The primary outcome is the proportion of patients in
      remission, defined as normalization of serum alanine transaminase (ALT) and immunoglobulin G
      (IgG) levels after 24 weeks of treatment, per treatment group. Secondary endpoints include
      safety and tolerability of mycophenolate mofetil, time to remission, changes in Model For
      End-Stage Liver Disease (MELD) -score (and its components bilirubin, INR, creatinine),
      albumin, pseudocholinesterase and N-terminal procollagen-III-peptide, ELF (Enhanced Liver
      Fibrosis) -score and aspects of quality of life. In a sub-study, drug levels will be
      measured.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2017</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Biochemical remission</measure>
    <time_frame>24 weeks</time_frame>
    <description>The percentage of patients in remission, defined as normalization of serum ALT and IgG levels after 24 weeks of treatment, per treatment group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to biochemical remission</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical remission at any time</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Partial remission, defined as alanine aminotransferase (ALT) or aspartate aminotransferase (AST) serum levels &gt;1x Upper Limit of Normal (ULN) and &lt;2x ULN</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimal response, defined as decrease of ALT or AST serum levels but still &gt;2x ULN</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment failure, defined as no improvement or increase of ALT or AST serum levels</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in liver stiffness, measured by transient elastography</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>N-terminal procollagen-III-peptide, ELF score</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in quality of life measured with Short Form Health survey 36 (SF-36)</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with treatment related adverse events per treatment group</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The level of liver enzymes in both groups</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steroid and other side-effects scores consisting of Visual Analogue Scores (VAS) scores (0 - 10) by the physician for Cushing-face, buffalo hump, acne, striae, bruising and hirsutism.</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with biochemical remission</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of ALT to lowest ALT ever</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>De novo onset of diabetes mellitus (requiring medication)</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypertension (requiring medication)</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glaucoma</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of infections</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extrahepatic AIH manifestations (e.g. arthralgia)</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient survival</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue index</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pruritis VAS score</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone fractures</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Osteoporosis (confirmed by bone densitometry)</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Autoimmune Hepatitis</condition>
  <arm_group>
    <arm_group_label>Mycophenolate mofetil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The intervention group will receive oral mycophenolate mofetil for 24 weeks. Both groups will be treated with steroid induction which will closely follow the schedule from the recent EASL Clinical Practice Guidelines.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Azathioprine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>. The control group will be treated with azathioprine (standard of care) for 24 weeks. Both groups will be treated with steroid induction which will closely follow the schedule from the recent EASL Clinical Practice Guidelines.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate mofetil</intervention_name>
    <arm_group_label>Mycophenolate mofetil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azathioprine</intervention_name>
    <arm_group_label>Azathioprine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Probable or definite diagnosis of autoimmune hepatitis according to the International
             Autoimmune Hepatitis Study Group criteria

          -  First presentation of AIH requiring treatment according to the current EASL guidelines

          -  Age â‰¥ 18 years

          -  Must provide informed consent and agree to comply with the trial protocol

        Exclusion Criteria:

          -  Overlap syndrome with Primary Sclerosing Cholangitis (PSC) or Primary Biliary
             Cholangitis (PBC) (Paris criteria, strong positive Anti-Mitochondrial Antibodies
             (AMA), past liver biopsy or cholangiographic findings compatible with PBC or PSC).

          -  Presentation with acute liver failure, defined as presence of hepatic encephalopathy
             and coagulopathy (INR &gt; 1.5)

          -  Current treatment with prednisone/prednisolone and/or immunosuppressive medication for
             an indication other than autoimmune hepatitis

          -  Current systemic infection

          -  Other clinically significant medical conditions that could interfere with the trial

          -  If female of childbearing potential: known pregnancy, or unwilling to practice
             anticontraceptive measures.

          -  History of noncompliance with medical regimens, or patients who are considered to be
             potentially unreliable or unable to participate

          -  Mental instability or incompetence, such that the validity of informed consent or
             compliance with the trial is uncertain
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bart van Hoek, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Leiden University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joost PH Drenth, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Simon Pape, MD</last_name>
    <phone>+31652621030</phone>
    <email>Simon.Pape@radboudumc.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Vrije Universiteit Medisch Centrum</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karin MJ van Nieuwkerk, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Karin MJ van Nieuwkerk, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Centre</name>
      <address>
        <city>Leiden</city>
        <zip>2333ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lida Beneken Kolmer</last_name>
      <phone>071-526 1188</phone>
      <email>A.Beneken_Kolmer@lumc.nl</email>
    </contact>
    <investigator>
      <last_name>Bart van Hoek, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sint Antonius Hospital</name>
      <address>
        <city>Nieuwegein</city>
        <zip>3430 EM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert C Verdonk, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Robert C Verdonk, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Radboud University Medical Centre</name>
      <address>
        <city>Nijmegen</city>
        <zip>6525GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simon Pape, MD</last_name>
      <phone>+31-6-52621030</phone>
      <email>Simon.Pape@radboudumc.nl</email>
    </contact>
    <investigator>
      <last_name>Joost PH Drenth, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Simon Pape, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 17, 2016</study_first_submitted>
  <study_first_submitted_qc>September 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2016</study_first_posted>
  <last_update_submitted>April 18, 2018</last_update_submitted>
  <last_update_submitted_qc>April 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Autoimmune</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Azathioprine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

